FollowSciClone Pharmaceuticals shares rose to their highest level since 2000 in mid-morning trade Thursday after the specialty pharmaceutical company reported better-than-expected Q4 results late Wednesday. Shares were most recently higher 17%, down from the earlier high of $9.65. The 52-week low is at $4.24.
The company said Q4 sales were $41.4 million, more than the Cap IQ estimate for $38.93 million. Non-GAAP EPS rose to $0.29 from $0.07 a year ago and beat estimates for $0.16.
Reported earnings rose to $3.5 million or $0.07 per diluted share from $36,000 or $0.00 per share a year earlier.
It sees FY15 sales between $153 million and $158 million, driven by ZADAXIN revenues, and non-GAAP EPS between $0.73 and $0.77. Analysts are looking for revenue of $155 million and EPS of $0.61.
